RxDoctor Payments Data

Shannon Hoos-Thompson, MD

Cardiovascular Disease · Kansas City, KSNPI 1720201502

Payments from drug & device makers

$2,861in general payments, 2019–2025

Across 95 payments — averaging $30.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$665
  • Medtronic$593
  • E.r. Squibb & Sons, L.L.C.$260
  • Amgen$235
  • Boston Scientific$225
  • Novo Nordisk$170
  • plus $712 from 12 others

What the payments were for

  • Speaking & faculty fees$50017%
  • Food & beverage$2,35882%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,861 in reported general payments places this provider in the 50th percentile of 175 cardiovascular disease providers in Kansas.

See all cardiovascular disease providers in Kansas

Medicare billing

Part B allowed, 2024
$143,047
Medicare patients
1,177
Services billed
1,983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$146,596
JardianceEmpagliflozin59$74,653
Repatha SureclickEvolocumab87$57,360
FarxigaDapagliflozin Propanediol44$51,576
EntrestoSacubitril/Valsartan35$31,181
Praluent PenAlirocumab41$27,449
XareltoRivaroxaban21$25,737
Atorvastatin Calcium260$2,678
Ezetimibe127$2,383
Spironolactone372$2,341
Rosuvastatin Calcium190$2,135
Metoprolol Succinate164$1,694
Losartan Potassium125$1,222
Ranolazine ErRanolazine22$1,118
Carvedilol142$1,001

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$665$146,596133 claims
Boehringer IngelheimJardiance$55$74,65359 claims
AstraZenecaFarxiga$128$51,57644 claims
NovartisEntresto$82$31,18135 claims
Johnson & JohnsonXarelto$65$25,73721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 175 cardiovascular disease providers in Kansas.

Other cardiovascular disease in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →